Oculis Holding AG

NASDAQ (USD): Oculis Holding AG (OCS)

Last Price


Today's Change

-0.01 (0.08%)

Day's Change

11.52 - 11.70

Trading Volume



Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare


CEO:  Dr. Riad Sherif M.B.A., M.D. Dr. Riad Sherif M.B.A., M.D.

Full Time Employees:  36 36

IPO Date:  2021-05-18 2021-05-18

CIK:  0001953530 0001953530

ISIN:  CH1242303498 CH1242303498


Beta:  0.08 0.08

Last Dividend:  0.00 0.00

Dcf Diff:  11.25 11.25

Dcf:  0.36 0.36


Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.


Bahnhofstrasse 7,
Zug, 6300, CH

41 58 810 0182


Be the first to like this. Showing 0 of 0 comments

Post a Comment